Pfizer Stock - Analyst consensus and valuation snapshot

Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/22/2026, 14:49 UTC. Details in the imprint.

Pfizer (US7170811035) trades well below its pre-pandemic highs while Wall Street maintains a broadly constructive view on the stock. Consensus data from several broker platforms indicate a moderate-buy stance with upside potential based on pipeline optionality and cost-cutting progress, according to current analyst overviews.

What current consensus shows

Across major platforms, Pfizer stock is currently characterized as a "moderate buy" based on aggregated broker recommendations. One consensus overview cites an average 12-month price target near $29.50, implying mid-teens percentage upside from recent levels, according to an analyst summary page. An eToro analyst consensus snapshot

The same overview lists a price-to-earnings ratio just below 20 and a dividend yield around the high single digits, underlining that a significant part of the expected return is meant to come from income. The rating spread typically skews towards buys and holds, with only a minority of explicit sell recommendations.

How the market prices Pfizer

Recent quote data place Pfizer shares in the mid-$20s, keeping the stock near multi-year lows and well off the 2021 pandemic peak above $50. One real-time retail brokerage quote shows the shares around $25.25, implying a market value near $144 billion. A Robinhood price and market cap overview

At these levels, the dividend yield stands in a high single-digit range, which is elevated versus many large-cap pharma peers. Valuation metrics such as forward earnings and cash flow multiples therefore reflect both the revenue cliff after COVID products and expectations that pipeline launches and cost cuts can gradually rebuild earnings.

Tuesday lens on analyst updates

From a Tuesday perspective, the focus lies on how analyst sentiment and estimates evolve rather than on a single rating move. Consensus still embeds a recovery path for earnings through the late 2020s, supported by management's stated plan to offset the post-pandemic revenue decline with new launches and productivity gains. Pfizer's quarterly reporting materials

Estimate revisions over the past quarters have generally been downward for near-term revenues as COVID vaccine demand normalizes, while longer-term projections depend heavily on execution in oncology, immunology and infectious diseases. Against this backdrop, investors should keep an eye on how upcoming trial readouts or regulatory decisions might trigger fresh target changes.

What the company sells

Pfizer generates revenue from a broad portfolio of prescription medicines and vaccines, including products in oncology, rare diseases, inflammation and immunology, internal medicine and hospital injectables. A widely known example from its current lineup is the pneumococcal vaccine Prevnar 20, alongside its COVID offerings Comirnaty and Paxlovid.

Where the stock trades today

Pfizer shares (US7170811035) trade on the New York Stock Exchange at approximately $25.25 as of 06/22/2026, 14:30 UTC.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.